Near-Infrared Fluorescence Molecular Imaging of Ductal Carcinoma in Situ with CD44v6-Specific Antibodies in Mice: A Preclinical Study

Molecular Imaging and Biology

Volumn 15, Issue 3, 2013, Pages 290-298

  Vermeulen, Jeroen F ^a   Van Brussel, Aram S A ^a   Adams, Arthur ^a   Mali, Willem P Th M ^a   Van Der Wall, Elsken ^a   Van Diest, Paul J ^a   Derksen, Patrick W B ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antibody; Breast cancer; DCIS; IRDye800CW; Mouse model; NIRF; Optical imaging

Indexed keywords

CD44V6 ANTIGEN; DYE; IRDYE800CW; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY LABELING; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; IMAGE ANALYSIS; IMAGING SYSTEM; IN VIVO STUDY; INTRADUCTAL CARCINOMA; MOLECULAR IMAGING; MOUSE; NEAR INFRARED FLUORESCENCE MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, CD44; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CELL LINE, TUMOR; FEMALE; FLUORESCENCE; HUMANS; INTRAOPERATIVE CARE; MAMMARY NEOPLASMS, ANIMAL; MICE; MOLECULAR IMAGING; TISSUE DISTRIBUTION;

MUS;

EID: 84877784814     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-012-0605-8     Document Type: Article

References (29)

1. 111In-cG250 imaging. J Nucl Med: Off Publ Soc Nucl Med 53:82-89
2. Hirche C, Murawa D, Mohr Z et al (2010) ICG fluorescence-guided sentinel node biopsy for axillary nodal staging in breast cancer. Breast Cancer Res Treat 121:373-378
3. Murawa D, Hirche C, Dresel S, Hunerbein M (2009) Sentinel lymph node biopsy in breast cancer guided by indocyanine green fluorescence. Br J Surg 96:1289-1294
4. Oude Munnink TH, Nagengast WB, Brouwers AH et al (2009) Molecular imaging of breast cancer. Breast 18(Suppl 3):S66-S73
5. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012-4021
6. Frangioni JV (2003) In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol 7:626-634
7. Vermeulen JF, van Brussel AS, van der Groep P et al (2012) Immunophenotyping invasive breast cancer: paving the road for molecular imaging. BMC Cancer 12:240
8. Fox SB, Fawcett J, Jackson DG et al (1994) Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54:4539-4546
9. Ponta H, Wainwright D, Herrlich P (1998) The CD44 protein family. Int J Biochem Cell Biol 30:299-305
10. Afify A, McNiel MA, Braggin J et al (2008) Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast. Appl Immunohistochem Mol Morphol 16:121-127
11. Foekens JA, Dall P, Klijn JG et al (1999) Prognostic value of CD44 variant expression in primary breast cancer. Int J Cancer 84:209-215
12. Schumacher U, Horny HP, Horst HA et al (1996) A CD44 variant exon 6 epitope as a prognostic indicator in breast cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol 22:259-261
13. Morris SF, O'Hanlon DM, McLaughlin R et al (2001) The prognostic significance of CD44s and CD44v6 expression in stage two breast carcinoma: an immunohistochemical study. Eur J Surg Oncol: J Eur Soc Surg Oncol Br Assoc Surg Oncol 27:527-531
14. Heider KH, Kuthan H, Stehle G, Munzert G (2004) CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother: CII 53:567-579
15. Orian-Rousseau V, Chen L, Sleeman JP et al (2002) CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16:3074-3086
16. Wobus M, Kuns R, Sheyn I et al (2002) Endometrial carcinoma cells are nonpermissive for CD44-erbB2 interactions. Appl Immunohistochem Mol Morphol 10:242-246
17. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P (1995) CD44 isoforms in prognosis of breast cancer. Lancet 346:502
18. Marhaba R, Zoller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35:211-231
19. van der Voort R, Taher TE, Wielenga VJ et al (1999) Heparan sulfate-modified CD44 promotes hepatocyte growth factor/scatter factor-induced signal transduction through the receptor tyrosine kinase c-Met. J Biol Chem 274:6499-6506
20. Postema EJ, Borjesson PK, Buijs WC et al (2003) Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. J Nucl Med: Off Publ Soc Nucl Med 44:1690-1699
21. Colnot DR, Roos JC, de Bree R et al (2003) Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother: CII 52:576-582
22. Koppe M, Schaijk F, Roos J et al (2004) Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with early-stage breast cancer. Cancer Biother Radiopharm 19:720-729
23. Wetterwald A, van der Pluijm G, Que I et al (2002) Optical imaging of cancer metastasis to bone marrow: a mouse model of minimal residual disease. Am J Pathol 160:1143-1153
24. Schackmann RC, van Amersfoort M, Haarhuis JH et al (2011) Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121:3176-3188
25. Oliveira S, van Dongen GA, Stigter-van Walsum M et al (2011) Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging. doi: 10.2310/7290.2011.00025
26. Themelis G, Yoo JS, Soh KS et al (2009) Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt 14:064012
27. Oliveira S, Cohen R, Stigter-van Walsum M et al (2012) A novel method to quantify IRDye800CW fluorescent antibody probes ex vivo in tissue distribution studies. EJNMMI Res 2:50
28. Heider KH, Sproll M, Susani S et al (1996) Characterization of a high-affinity monoclonal antibody specific for CD44v6 as candidate for immunotherapy of squamous cell carcinomas. Cancer Immunol Immunother: CII 43:245-253
29. Terwisscha van Scheltinga AG, van Dam GM et al (2011) Intraoperative near-infrared fluorescence tumor imaging with vascular endothelial growth factor and human epidermal growth factor receptor 2 targeting antibodies. J Nucl Med: Off Publ Soc Nucl Med 52:1778-1785